Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Prospective Trail of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Recurrent Ovarian Cancer Patients With Mutations in Homologous Recombination Repair (HRR) Genes

NCT04473339 is registered in ClinicalTrials.gov with CAI Hongbing as lead sponsor.

NCT NCT04473339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04473339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Prospective Trail of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Recurrent Ovarian Cancer Patients With Mutations in Homologous Recombination Repair (HRR) Genes
Lead sponsor
CAI Hongbing
Phase
Phase 3
Overall status
Unknown status
Start date
August 1, 2020
Completion date
December 30, 2023
Enrollment
280 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer, homologous recombination repair gene mutation, hyperthermic intraperitoneal chemotherapy(hipec), ovarian cancer, ovarian cancer, epithelial